Evaluation of the Efficacy of an inTerdialytic "Ethanol 40% v/v - enoxapaRin 1000 U/mL" Lock solutioN to Prevent Tunnelled Catheter Infections in Chronic Hemodialysis Patients
Launched by UNIVERSITY HOSPITAL, CLERMONT-FERRAND · Mar 13, 2017
Trial Information
Current as of November 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a special solution made of ethanol and a blood thinner called enoxaparin, which is used to help prevent infections in patients who have a tunnelled catheter for hemodialysis. Hemodialysis is a treatment for patients with end-stage kidney disease, where a machine cleans their blood. The researchers want to see if this new solution can help keep the catheter, which is a tube inserted into the body for dialysis, free from infections.
To participate in this study, individuals need to be between 65 and 74 years old, have end-stage kidney disease, and be receiving hemodialysis at least three times a week, with their catheter in place for at least two weeks. Participants will need to provide written consent and have health insurance coverage. If eligible, patients will be part of a study that aims to improve their care and potentially reduce the risk of infections related to their catheters.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • end-stage renal disease
- • chronic hemodialysis/hemodiafiltration at least three times a week
- • functional TC inserted for at least two weeks
- • Social security cover
- • Written informed consent
- Exclusion Criteria:
- • -
About University Hospital, Clermont Ferrand
The University Hospital of Clermont-Ferrand is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its multidisciplinary approach, the hospital integrates cutting-edge scientific inquiry with patient care, fostering an environment that promotes collaboration among healthcare professionals, researchers, and academic partners. With a strong commitment to improving patient outcomes, the institution actively engages in a wide array of clinical studies, ranging from early-phase trials to large-scale interventions, aimed at addressing critical health challenges and enhancing treatment modalities. Its state-of-the-art facilities and expertise make it a pivotal contributor to clinical research in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Clermont Ferrand, France
Patients applied
Trial Officials
Julien ANIORT
Principal Investigator
University Hospital, Clermont-Ferrand
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials